Ather­sys tries to post-hoc-an­a­lyze its way out of an­oth­er tri­al fail for stroke stem cell ther­a­py

Ather­sys’ stem cell ther­a­py has failed yet again.

In a 206-per­son tri­al con­duct­ed in Japan, Ather­sys’ stem cell ther­a­py for stroke failed its pri­ma­ry end­point …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.